Table of Content

Executive Summary
Scope of the Study
Research Methodology

1 Markets
1.1 Market Outlook
1.1.1 Market Overview
1.1.2 Product Definition
1.1.3 Inclusion and Exclusion Criteria
1.1.4 Key Findings
1.2 Industry Outlook
1.2.1 Regulatory Framework
1.2.1.1 Regulatory Framework in Europe
1.2.2 Reimbursement Scenario
1.2.2.1 Fecal Immunochemical Testing/Fecal Occult Blood Testing
1.2.2.2 Molecular Testing
1.2.3 Patent Analysis
1.2.3.1 Patent Filing Trend (by Country)
1.2.3.2 Patent Filing Trend (by Year)
1.2.4 Key Trends
1.2.4.1 Rise of At-Home Colorectal Cancer Screening
1.2.4.2 Multimodal Approaches to Colorectal Cancer Screening
1.2.4.3 Use of Gut Microbiota in Colorectal Cancer Diagnosis
1.2.5 COVID-19 Impact
1.2.5.1 Impact of COVID-19 on Colorectal Cancer Screening and Diagnostic Market
1.2.5.2 Pre-COVID-19 Phase
1.2.5.3 During-COVID-19 Phase
1.2.5.4 Post-COVID-19 Phase
1.2.6 Product Landscape
1.2.7 Product Pipeline
1.2.8 Business Dynamics
1.2.8.1 Impact Analysis
1.2.8.2 Business Drivers
1.2.8.2.1 Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare
1.2.8.2.2 Advances in Genomics and Molecular Diagnostics
1.2.8.2.3 Growing Demand for Colorectal Cancer Testing
1.2.8.2.4 Earlier Cancer Detection Enabling Reduced Treatment Cost
1.2.8.3 Business Restraints
1.2.8.3.1 Limited Sensitivity of FIT/FOBt Testing Kits
1.2.8.3.2 Challenges with Sample Collection
1.2.8.4 Business Opportunities
1.2.8.4.1 Expansion of Screening Programs
1.2.8.4.2 Emerging Markets Proposing Significant Untapped Potential

2 Colorectal Cancer Screening and Diagnostic Market (by Region)
2.1 Europe
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Colorectal Cancer Screening and Diagnostic Market (by End User)
2.1.3.2 Europe Colorectal Cancer Screening and Diagnostic Market (by Product)
2.1.3.3 Europe Colorectal Cancer Screening and Diagnostic Market (by Country)
2.1.3.3.1 Germany
2.1.3.3.2 U.K.
2.1.3.3.3 France
2.1.3.3.4 Spain
2.1.3.3.5 Italy
2.1.3.3.6 Rest-of-Europe
2.2 Competitive Benchmarking
2.2.1 Key Strategies and Developments
2.2.1.1 Funding Activities
2.2.1.2 New Offerings
2.2.1.3 Business Expansion
2.2.1.4 Mergers and Acquisitions
2.2.1.5 Partnerships and Collaborations
2.3 Company Profile
2.3.1 Epigenomics AG
2.3.1.1 Company Overview
2.3.1.2 Role of Epigenomics AG in the Colorectal Cancer Screening and Diagnostic Market
2.3.1.3 Financials
2.3.1.4 Recent Developments
2.3.1.5 Analyst Perspective
2.3.2 Mainz Biomed NV
2.3.2.1 Company Overview
2.3.2.2 Role of Mainz Biomed NV in the Colorectal Cancer Screening and Diagnostic Market
2.3.2.3 Financials
2.3.2.4 Recent Developments
2.3.2.5 Analyst Perspective
2.3.3 Novigenix SA
2.3.3.1 Company Overview
2.3.3.2 Role of Novigenix SA in the Colorectal Cancer Screening and Diagnostic Market
2.3.3.3 Recent Developments
2.3.3.4 Analyst Perspective
List of Figures
Figure 1: Europe Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
Figure 2: Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
Figure 3: Europe Colorectal Cancer Screening and Diagnostic Market (by Type), $Billion 2022 and 2033
Figure 4: Europe Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion 2022 and 2033
Figure 5: Colorectal Cancer Screening and Diagnostic Market: Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Top-Down Approach (Segment-Wise Analysis)
Figure 9: Colorectal Cancer Screening and Diagnostic Market, Patent Analysis (by Country), January 2019-April 2023
Figure 10: Colorectal Cancer Screening and Diagnostic Market, Patent Analysis (by Year), January 2019-April 2023
Figure 11: Stool-Based Molecular Tests, by Company
Figure 12: Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
Figure 13: Number of Colorectal Cancer Cases Globally, 2020- 2040
Figure 14: Cancer Survival Rate with Respect to Stage of Detection, 2022
Figure 15: Colorectal Cancer Screening and Diagnostic Market, %Share (by Region), 2022 and 2033
Figure 16: Europe Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
Figure 17: Europe Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion, 2022-2033
Figure 18: Europe Colorectal Cancer Screening and Diagnostic Market (by Product), $Billion, 2022-2033
Figure 19: Europe Colorectal Cancer Screening and Diagnostic Market (by Country), Share (%), 2022 and 2033
Figure 20: Germany Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
Figure 21: U.K. Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
Figure 22: France Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
Figure 23: Spain Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
Figure 24: Italy Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
Figure 25: Rest-of-Europe Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
Figure 26: Colorectal Cancer Screening and Diagnostic Market, Number of Key Developments and Strategies, January 2020-April 2023
Figure 27: Funding Activities, January 2020-April 2023
Figure 28: New Offerings, January 2020-April 2023
Figure 29: Business Expansion, January 2020-April 2023
Figure 30: Mergers and Acquisitions, January 2020-April 2023
Figure 31: Partnerships and Collaborations, January 2020-April 2023
Figure 32: Epigenomics AG: Product Portfolio
Figure 33: Epigenomics AG: Overall Financials, $Million, 2020-2022
Figure 34: Epigenomics AG: Net Revenue (by Segment), $Million, 2020-2022
Figure 35: Epigenomics AG: Net Revenue (by Region), $Million, 2020-2022
Figure 36: Mainz Biomed NV: Product Portfolio
Figure 37: Mainz Biomed NV: Overall Financials, $Million, 2020-2022
Figure 38: Novigenix SA: Product Portfolio
List of Tables
Table 1: Colorectal Cancer Screening and Diagnostic Market, Key Developments Analysis, January 2018-April 2023
Table 2: Key Questions Answered in the Report
Table 3: Colorectal Cancer Screening and Diagnostic Market, Product Pipeline
Table 4: Examples of Colorectal Cancer Screening Initiatives
Table 5: Examples of Product Launches and Approval in Asia-Pacific
Table 6: Europe Colorectal Cancer Screening and Diagnostic Market, Impact Analysis